Recent Updates
Recently added Catalysts

OptiNose, Inc.

OPTNFDA catalysts, PDUFA dates & pipeline intelligence
$9.6
▼ -0.07 · -0.72%

Last traded May 20, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full OPTN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $4.8252W HIGH $20.03
Volume
860.96 K
Value Traded
8.27 M
Short % Float
1.64%
Days to Cover
8.4
+1.59%Week
+4.23%1 Month
+58.94%3 Month
+68.42%6 Month
-85.12%5 Year
-96.8%All Time

Cash Data

Unlock OPTN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
97.22 M
EPS (TTM)
-2.69
P/E Ratio
-
Ent. Value
152.68 M
Total Shares
10.13 M
Float Shares
7.91 M
Insiders
20.00%
Institutions
58.56%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every OPTN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

OPTN Catalyst Timeline

Dated clinical, regulatory and corporate events for OptiNose, Inc.

Unlock the full OPTN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How OPTN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all OPTN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Showing 3 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
OPN-375 Small moleculeNCT06850805Chronic Rhinosinusitis Without Nasal PolypsPhase 3 RECRUITING 84Oct 31, 2028
OPN-375 Small moleculeCompletedNCT03960580Chronic RhinosinusitisPhase 3 COMPLETED 555May 4, 2022
OPN-375 Small moleculeCompletedNCT03747458Bilateral Nasal PolyposisPhase 3 COMPLETED 40Jun 11, 2026
Unlock the OPTN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every OPTN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
XHANCE chronic sinusitisPhase 32022-10-21greater than 60% reduction in acute exacerbations and need for antibioticsRead MoreOptinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022Read More
Scroll for more · summaries link to the source press release
Unlock every OPTN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock OPTN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Marino Michael F IIIOfficer (Chief Legal Officer & Corp Sec)Sell -246 55,038 held$5.61 03/18/2025
Unlock the full OPTN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in OPTN

Fund % of Portfolio Current MV Shares Owned Activity
Opaleye Management Inc. 0.4 % (300 %) 1.77 M 193.04 K 112.2% ( 102.07 K)
Unlock every fund holding OPTN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in OPTN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see OPTN ownership
Insider and institutional ownership, quarter by quarter.

OPTN Short Interest

Shares sold short, counted twice a month.

1.64%
Short % of Float
of tradable shares sold short
130.6K
Shares Sold Short
-1.5% vs prior count
8.4 High
Days to Cover
trading days of normal volume to buy every short share back
15.6K
Avg Daily Volume
the average used for days to cover
Unlock OPTN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock OPTN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live OPTN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock OPTN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How OPTN ranks across every disease it competes in

Competitive Position is a premium feature
See how OPTN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

OPTN News

About OptiNose, Inc.

Founded13-10-2017
BIOPHARMAWATCH ELITE PLUS
Trade the next OPTN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime